FibroGen Reports Fiscal 2016 Financial Results
March 01, 2017 16:02 ET
|
FibroGen, Inc.
SAN FRANCISCO, March 01, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today reported financial results for the year ended December 31, 2016, and...
FibroGen Reports Financial Results for the Second Quarter of 2016
August 08, 2016 16:02 ET
|
FibroGen, Inc.
Enrollment Completed in Placebo-Controlled Study of FG-3019 (Pamrevlumab) in IPF China Phase 3 Top Line Data Expected by Year-End 2016 –Webcast Conference Call Scheduled for 4:30pm EDT Today– ...
Astellas and FibroGen Announce First Patient Treated in Phase 3 Studies and Positive Phase 2 Results of Roxadustat in Patients with Chronic Kidney Disease in Japan
July 25, 2016 21:00 ET
|
FibroGen, Inc.
TOKYO and SAN FRANCISCO, July 25, 2016 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE:4503) (“Astellas”) and FibroGen, Inc. (Nasdaq:FGEN) (“FibroGen”), today announced the dosing of the first...
FibroGen to Present at the Goldman Sachs 37th Annual Global Healthcare Conference
June 06, 2016 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, June 06, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), announced that Chief Executive Officer, Thomas B. Neff, will be presenting at the Goldman Sachs 37th Annual Global...
FibroGen Reports Financial Results for the First Quarter of 2016
May 09, 2016 16:02 ET
|
FibroGen, Inc.
Continued Progress in Roxadustat Phase 3 Studies; Promising Interim Pancreatic Cancer Data –Webcast Conference Call Scheduled for 4:30pm EST Today– SAN FRANCISCO, May 09, 2016 (GLOBE NEWSWIRE)...
FibroGen to Report First Quarter 2016 Financial Results on May 9, 2016
May 02, 2016 16:05 ET
|
FibroGen, Inc.
SAN FRANCISCO, May 02, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Promising Phase 2 Data Show Roxadustat Corrected Anemia in Chronic Kidney Disease Patients Before Intervention with Dialysis
April 20, 2016 23:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, April 20, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq:FGEN) (“FibroGen”), a research-based biopharmaceutical company, today announced that the Clinical Journal of the American...